Related references
Note: Only part of the references are listed.Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells
Hisamitsu Ide et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
Suzanne A. Eccles et al.
CANCER RESEARCH (2008)
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2008)
Triple negative breast cancer: current understanding of biology and treatment options
Soonmo Peter Kang et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2008)
Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis
Arkadiusz Z. Dudek et al.
INVESTIGATIONAL NEW DRUGS (2008)
Discovery and development of purine-scaffold Hsp90 inhibitors
Gabriela Chiosis et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
Roles of AKT signal in breast cancer
Wen Liu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Deconstructing the molecular portrait of basal-like breast cancer
Fruma Yehiely et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
Fumitaka Koga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Lyubomir T. Vassilev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Breast cancer in African-American women: differences in tumor biology from European-American women
Kandace Amend et al.
CANCER RESEARCH (2006)
Hsp70 molecular chaperones: Emerging roles in human disease and identification of small molecule modulators
Jeffrey L. Brodsky et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
ER Glaze et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
M Hollingshead et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts
JL Eiseman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Hsp90: an emerging target for breast cancer therapy
J Beliakoff et al.
ANTI-CANCER DRUGS (2004)
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
WD Foulkes et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance
Y Fernández et al.
CELL DEATH AND DIFFERENTIATION (2000)